Gemina Laboratories Stock Net Income
| GLABF Stock | USD 0.05 0.00 0.00% |
As of the 29th of January, Gemina Laboratories retains the Market Risk Adjusted Performance of 0.4157, risk adjusted performance of (0.02), and Standard Deviation of 19.29. Gemina Laboratories technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Gemina Laboratories treynor ratio, as well as the relationship between the value at risk and kurtosis to decide if Gemina Laboratories is priced fairly, providing market reflects its last-minute price of 0.05 per share. As Gemina Laboratories appears to be a penny stock we also urge to confirm its jensen alpha numbers.
Gemina Laboratories' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Gemina Laboratories' valuation are provided below:Gemina Laboratories does not presently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Gemina |
Gemina Laboratories 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Gemina Laboratories' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Gemina Laboratories.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Gemina Laboratories on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Gemina Laboratories or generate 0.0% return on investment in Gemina Laboratories over 90 days. Gemina Laboratories is related to or competes with Telescope Innovations, Propanc Biopharma,, and Cell Source. Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vit... More
Gemina Laboratories Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Gemina Laboratories' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Gemina Laboratories upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 144.07 | |||
| Value At Risk | (27.54) |
Gemina Laboratories Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Gemina Laboratories' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Gemina Laboratories' standard deviation. In reality, there are many statistical measures that can use Gemina Laboratories historical prices to predict the future Gemina Laboratories' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.57) | |||
| Total Risk Alpha | (2.38) | |||
| Treynor Ratio | 0.4057 |
Gemina Laboratories January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | 0.4157 | |||
| Mean Deviation | 6.19 | |||
| Coefficient Of Variation | (2,904) | |||
| Standard Deviation | 19.29 | |||
| Variance | 372.16 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.57) | |||
| Total Risk Alpha | (2.38) | |||
| Treynor Ratio | 0.4057 | |||
| Maximum Drawdown | 144.07 | |||
| Value At Risk | (27.54) | |||
| Skewness | 3.04 | |||
| Kurtosis | 22.43 |
Gemina Laboratories Backtested Returns
Gemina Laboratories holds Efficiency (Sharpe) Ratio of -0.0782, which attests that the entity had a -0.0782 % return per unit of risk over the last 3 months. Gemina Laboratories exposes eighteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Gemina Laboratories' Risk Adjusted Performance of (0.02), market risk adjusted performance of 0.4157, and Standard Deviation of 19.29 to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of -1.66, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Gemina Laboratories are expected to decrease by larger amounts. On the other hand, during market turmoil, Gemina Laboratories is expected to outperform it. At this point, Gemina Laboratories has a negative expected return of -1.48%. Please make sure to check out Gemina Laboratories' jensen alpha, kurtosis, relative strength index, as well as the relationship between the value at risk and day median price , to decide if Gemina Laboratories performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.57 |
Modest predictability
Gemina Laboratories has modest predictability. Overlapping area represents the amount of predictability between Gemina Laboratories time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Gemina Laboratories price movement. The serial correlation of 0.57 indicates that roughly 57.0% of current Gemina Laboratories price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.57 | |
| Spearman Rank Test | -0.16 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Gemina Laboratories reported net income of (4.73 Million). This is 101.39% lower than that of the Healthcare sector and 106.76% lower than that of the Biotechnology industry. The net income for all United States stocks is 100.83% higher than that of the company.
Gemina Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gemina Laboratories' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Gemina Laboratories could also be used in its relative valuation, which is a method of valuing Gemina Laboratories by comparing valuation metrics of similar companies.Gemina Laboratories is currently under evaluation in net income category among its peers.
Gemina Fundamentals
| Return On Equity | -3.47 | |||
| Return On Asset | -1.48 | |||
| Operating Margin | 979.18 % | |||
| Current Valuation | 17.22 M | |||
| Shares Outstanding | 64.1 M | |||
| Shares Owned By Insiders | 56.28 % | |||
| Price To Book | 9.70 X | |||
| Price To Sales | 5,790 X | |||
| EBITDA | (4.69 M) | |||
| Net Income | (4.73 M) | |||
| Cash And Equivalents | 2.95 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 12.47 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 2.50 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (3.87 M) | |||
| Earnings Per Share | (0.08) X | |||
| Market Capitalization | 33.65 M | |||
| Total Asset | 1.42 M | |||
| Net Asset | 1.42 M |
About Gemina Laboratories Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gemina Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gemina Laboratories using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gemina Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Gemina Pink Sheet
Gemina Laboratories financial ratios help investors to determine whether Gemina Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Gemina with respect to the benefits of owning Gemina Laboratories security.